News | October 22, 2007

SPIRIT III Shows Less MACE for Xience than Taxus

October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent, researchers reported at TCT 2007.
The rate of the primary endpoint, in-segment late loss was also reduced by 50 percent with the Xience V stent compared to Taxus. There were no significant differences in other secondary endpoints between the two stent types, including target vessel failure and stent thrombosis.
“Both the primary endpoint of the trial and the major secondary endpoint were met. Moeover, the reduction in major adverse cardiac events with the Xience V stent compared to the Taxus stent is an important finding that signifies improved long-term outcomes for patients with heart disease,” said Gregg W. Stone, M.D., chairman, Cardiovascular Research Foundation, professor of Medicine, Columbia University Medical Center.

For more information: www.crf.org

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init